A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-4508 in subjects with locally advanced or metastatic non-small cell lung cancer; Evaluate the pharmacokinetic (PK) characteristics of HRS-4508 and other efficacy endpoints for the treatment of locally advanced or metastatic non-small cell lung cancer.
Solid Tumor
DRUG: HRS-4508 tablet
The incidence and severity of adverse events (AE)/serious adverse events (SAE) (rated based on CTCAE v5.0), 2 years|Objective response rate (ORR), 1 year
Blood concentrations of HRS-4508, 12 weeks|Duration of response (DoR), 1 year|Disease control rate (DCR), 1 year|Progression free survival (PFS), 1 year|Overall survival (OS), 2 years
The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-4508 in subjects with locally advanced or metastatic non-small cell lung cancer; Evaluate the pharmacokinetic (PK) characteristics of HRS-4508 and other efficacy endpoints for the treatment of locally advanced or metastatic non-small cell lung cancer.